CRISPR Cas Genes Market

CRISPR (clustered regularly interspaced short palindromic repeats) is a family of DNA sequences found in the genomes of prokaryotic organisms such as bacteria and archaea. These sequences are derived from DNA fragments of bacteriophages that had previously infected the prokaryote. They are used to detect and destroy DNA from similar bacteriophages during subsequent infections. Hence these sequences play a key role in the antiviral (i.e. anti-phage) defense system of prokaryotes.

Cas9 (or "CRISPR-associated protein 9") is an enzyme that uses CRISPR sequences as a guide to recognize and cleave specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within organisms. This editing process has a wide variety of applications including basic biological research, development of biotechnology products, and treatment of diseases.

Diagram of the CRISPR prokaryotic antiviral defense mechanism. The CRISPR-Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages and provides a form of acquired immunity. RNA harboring the spacer sequence helps Cas (CRISPR-associated) proteins recognize and cut foreign pathogenic DNA.

Other RNA-guided Cas proteins cut foreign RNA. CRISPR are found in approximately 50% of sequenced bacterial genomes and nearly 90% of sequenced archaea.

CRISPR Cas Genes Market contains market size and forecasts of CRISPR & Cas Genes in Global, including the following market information:

Global CRISPR & Cas Genes Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global CRISPR & Cas Genes market was valued at 2878.8 million in 2021 and is projected to reach US$ 4894.3 million by 2028, at a CAGR of 7.9% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Vector-based Cas Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of CRISPR & Cas Genes include CRISPR Therapeutics, AstraZeneca, Addgene, Caribou Biosciences, Inc., Cellectis, Editas Medicine, Inc., Egenesis, F. Hoffmann-La Roche Ltd. and Horizon Discovery Group Plc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the CRISPR & Cas Genes companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global CRISPR & Cas Genes Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global CRISPR & Cas Genes Market Segment Percentages, by Type, 2021 (%)

Vector-based Cas

DNA-free Cas

Cell Line Engineering

Global CRISPR & Cas Genes Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global CRISPR & Cas Genes Market Segment Percentages, by Application, 2021 (%)

Biotechnology and Pharmaceutical Companies

Academics and Government Research Institutes

Contract Research Organizations (CROs)

Global CRISPR & Cas Genes Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global CRISPR & Cas Genes Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies CRISPR & Cas Genes revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies CRISPR & Cas Genes revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

CRISPR Therapeutics

AstraZeneca

Addgene

Caribou Biosciences, Inc.

Cellectis

Editas Medicine, Inc.

Egenesis

F. Hoffmann-La Roche Ltd.

Horizon Discovery Group Plc

Genscrip

Danaher Corporation

Intellia Therapeutics, Inc.

Lonza

Merck KGaA

New England BioLabs

Takara Bio, Inc.

Synthego

Mammoth Biosciences

Inscripta, Inc.

Cibus